SIM 0272
Alternative Names: SCR-6277; SCR-6920; SIM-0272Latest Information Update: 16 Jul 2026
At a glance
- Originator Simcere Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 17 Apr 2026 SIM 0272 is still in phase I development in phase-I development in Non-Hodgkin's-lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Capsule) (NCT05528055)
- 17 Apr 2026 SIM 0272 is still in phase I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Capsule) (NCT05528055)
- 17 Apr 2026 Pharmacodynamics data from preclinical data in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)